Pro Login

Novo Nordisk Shares Drop 14% After Sales Warning for 2026

Briefs Media Newspaper Logo Market Briefs
Briefs Finance
Published Feb 3, 2026
Share:
A tablet displays a red downward stock chart next to a calendar marked 2026, an injection device, a vial, and financial documents on a desk, reflecting the impact of a sales warning on Novo Nordisk shares.
Summary:
  • Novo Nordisk's U.S. shares fell 14% after the company warned of lower sales and profit growth for 2026.
  • The company anticipates sales and operating profit declines of 5% to 13% at constant exchange rates.
  • In 2025, Novo Nordisk reported a 10% increase in sales and a 6% increase in operating profit.

Sales Warning Affects Stock Performance

Novo Nordisk's shares plummeted on Tuesday, falling as much as 14% after the company announced a decline in sales and profit growth for 2026.

The company pointed to lower prices in the U.S. and the loss of exclusivity for its popular drugs, Wegovy and Ozempic, in several international markets, including China, Brazil, and Canada.

Declining Profit Outlook

For the upcoming year, Novo Nordisk expects sales and operating profits to decline between 5% and 13% at constant exchange rates.

This forecast is significantly worse than what analysts had anticipated. The company is currently facing challenges in its largest market, the U.S., which is impacting its overall performance.

Performance Review for 2025

Despite the ominous outlook for 2026, Novo Nordisk reported a 10% increase in sales and a 6% increase in operating profit for 2025.

In the fourth quarter, the company saw net sales total 79.1 billion Danish kroner, which is equivalent to about $12.5 billion, slightly exceeding the analysts' expectations of 77.8 billion kroner.

Key Drug Sales Figures

In the fourth quarter, Novo Nordisk's best-selling drug, Ozempic, generated sales of 31.8 billion kroner, marking a 1% increase compared to the same period last year.

Additionally, Wegovy sales reached 21.9 billion kroner, reflecting a 17% increase year-over-year.

Market Competition and Future Plans

With increasing competition from Eli Lilly's weight-loss drug, tirzepatide, Novo Nordisk is striving to regain market share in the U.S. market.

The company is optimistic about launching Wegovy in more countries in 2026 and introducing a higher 7.2 mg dose in several markets.

What’s Next for Novo Nordisk?

Moving forward, Novo Nordisk is focusing on the U.S. launch of the oral version of Wegovy. CEO Mike Doustdar expressed confidence in the drug's potential to drive volume growth in the coming years, despite the current pricing pressures and competition.

Investors remain cautious, however, as they await updates on Novo’s strategy to navigate the shifting market dynamics.

Disclosure

Get Market Briefs delivered to your inbox every morning for free!

Homepage V1 opt-in (#63)
No fluff. No noise. No politics. Just finance news you can read in 5 minutes.

Blogs

February 11, 2026
Why Is RCAT Stock Surging? Red Cat's American Drone Bet

In 2026, the drone economy is starting to take off. […]

Read More
February 9, 2026
ETF vs Mutual Fund vs Index Fund: Which One Is Right For You?

If you're looking to start investing but don't want to […]

Read More
February 8, 2026
What Are Stock Futures? A Beginner's Guide To Understanding Futures Contracts

If you've ever checked the market before opening bell and […]

Read More
February 8, 2026
Certificate of Deposits: Are CDs A Good Investment? What Investors Need To Know

What Is a CD (Certificate of Deposit)? A certificate of […]

Read More
February 8, 2026
ABAT Stock: Will American Battery Technology Solve America’s Lithium Problem?

Critical minerals have been a hot topic over the past […]

Read More
February 7, 2026
Is Copper A Good Investment? What Most Investors Are Missing Right Now

Since late July 2025, the price of copper has jumped […]

Read More
February 6, 2026
Bull Market vs Bear Market: What Investors Need to Know

Between January and October 2022, markets were in turmoil because […]

Read More
February 6, 2026
What Is a Moat? Warren Buffett’s Favorite Stock Valuation Metric

There are 195 countries in the world - most have […]

Read More
February 5, 2026
What Does a Negative P/E Ratio Mean? A Simple Guide for Investors

Many companies have revenue - which is money generated usually […]

Read More
February 3, 2026
NU Stock: Why This Neobank Is Becoming a Major Player

While U.S. neobanks like Chime and SoFi grab headlines, Nu […]

Read More
1 2 3 9
Share via
Copy link